Search research articles
Contact Us
Filters
Showing results (161-170 of 164) with videos related to
Page
of 17
Sort By:
You have reached the last page of results.
This site can display upto 164 results.
BMJ (Clinical Research Ed.)
|
June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Munyaradzi Dimairo, Philip Pallmann, James Wason, et al.
The AAPS Journal
|
March 31, 2011
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop
Jane P F Bai, Robert Bell, ShaAvhree Buckman, et al.
Neurology
|
April 5, 2015
Challenges and opportunities in designing clinical trials for neuromyelitis optica
Brian G Weinshenker, Gerard Barron, Jacinta M Behne, et al.
Eclinicalmedicine
|
February 3, 2026
Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial
M Parellada, A San José Cáceres, R Delorme, et al.
Page
of 17
Search research articles
Search
Showing results (161-170 of 164) with videos related to
Sort By:
Page
of 17
You have reached the last page of results.
This site can display upto 164 results.
BMJ (Clinical Research Ed.)
|
June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Munyaradzi Dimairo, Philip Pallmann, James Wason, et al.
The AAPS Journal
|
March 31, 2011
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop
Jane P F Bai, Robert Bell, ShaAvhree Buckman, et al.
Neurology
|
April 5, 2015
Challenges and opportunities in designing clinical trials for neuromyelitis optica
Brian G Weinshenker, Gerard Barron, Jacinta M Behne, et al.
Eclinicalmedicine
|
February 3, 2026
Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial
M Parellada, A San José Cáceres, R Delorme, et al.
Page
of 17